Challenges in the Clinical Advancement of Cell Therapies for Parkinson’s Disease
Scientists discuss how challenges pertaining to cell sources, functional and safety testing, manufacturing, and address clinical-trial design to advance the development of cell therapies for Parkinson’s disease.
[Mucosal Immunology] Investigators review novel findings on the emerging role of mesenchymal cells in this process using insights gained from lineage tracing approaches, Cre-based genes deletion and single cells transcriptomics.
[Cell Death Discovery] Human hepatoma PLC/PRF/5-ASBT and THP1 cell lines or primary mouse hepatocytes were used for mechanistic studies. Hepatic TNFRSF12A expression was markedly increased in obstructive cholestasis or primary biliary cholangitis patients.